- ZEN Graphene Solutions (ZEN) has executed a reorganisation of the company’s current corporate leadership structure
- The company has appointed one of its directors, Gregory Fenton, as its new CEO
- ZEN Graphene also confirmed Dr Francis Dubé as Executive Chairman of the Board, a role he assumed in May 2018
- Additionally, the company has appointed a Vice President of Science and Research, and created the Office of the CEO
- ZEN Graphene Solutions is down 0.61 per cent and is currently trading for C$1.62 per share
ZEN Graphene Solutions (ZEN) has executed a reorganisation of the company’s current corporate leadership structure.
Most notably, the company has appointed a member of its Board of Directors, Gregory Fenton, as its new CEO. Gregory is a chartered financial analyst, who has been instrumental in steering ZEN Graphene’s strategic direction since July 2018.
The company has also confirmed Dr Francis Dubé as the Executive Chairman of the Board. Dr Dubé first assumed this role in May of 2018, in the absence of a formal Chairman.
Since then, Dr Dubé has seen ZEN Graphene transform from an exploration and development company into a graphene technology business. He has led the company through the unique challenges posed by the COVID-19 pandemic, turning it into an opportunity to apply graphene-based solutions to the viral problem.
As part of the reorganisation, ZEN Graphene has also created the Office of the CEO, which will comprise both Gregory and Dr Dubé. The company’s new CEO and Executive Chairman will work together to determine ZEN Graphene’s strategic direction, especially concerning the company’s patent-pending graphene-based viricidal coating.
ZEN Graphene’s Executive Chairman, Dr Francis Dubé, commented on the reorganisation of the company’s corporate structure.
“It is an honour to be appointed Executive Chairman of the Board and continue working with Mr Fenton, our new CEO as part of the Office of the CEO, to build a world-leading graphene technology company,” he said.
“We have established a solid foundation over the last few years, and ZEN is now poised for significant growth with the commercial launch of our viricidal coating and our solid research and development pipeline,” he added.
In addition to ZEN Graphene’s shake-up of its leadership team, the company has also announced an appointment in another department. The company’s Head of Research, Dr Colin van der Kuur, has been appointed as Vice President of Science and Research.
Dr van der Kuur has had an essential role in guiding ZEN Graphene’s research program, and will continue to do so in his new position.
ZEN Graphene Solutions is down 0.61 per cent and trading for C$1.62 per share, as of 10:14am EST.